Research Brief
BPC-157: Research Overview
A synthetic pentadecapeptide studied in preclinical models for tissue repair, gut protection, and the nervous system — not approved for human use.
Last reviewed: June 2, 2026
For Laboratory Research Use Only
Content on this page describes published research findings. LUMEN BASED does not make therapeutic claims. Consult the primary literature and your institutional review board for protocol design. These products are not for human consumption.
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic peptide of 15 amino acids — a "pentadecapeptide" — with a sequence derived from a protein found in human gastric juice. In the literature it is described as a "stable gastric pentadecapeptide," studied for a broad range of tissue-protective effects in laboratory models, and often characterized as "pleiotropic" (one compound influencing many tissues in animal experiments). [Józwiak 2025]
It is important to state plainly: BPC-157 is not approved by the FDA or any major regulatory agency for human use, and the existing evidence is overwhelmingly preclinical. [Józwiak 2025; McGuire 2025]
What the research has investigated
Musculoskeletal & soft-tissue healing
The largest body of BPC-157 research concerns soft-tissue repair. A review of the musculoskeletal literature reports that animal studies of tendon, ligament, and muscle injury have "consistently" shown positive healing effects — while explicitly noting that efficacy "is yet to be confirmed in humans." [Gwyer 2019]
Tendon cells & mechanism
At the cellular level, an in vitro and ex vivo study using animal-derived tendon tissue found that BPC-157 accelerated the outgrowth of tendon explants and increased tendon fibroblast survival and migration, with the effect attributed to activation of the FAK–paxillin signaling pathway. These findings are from cell and tissue models, not humans. [Chang 2011]
Wound healing
A separate review focused on skin and tissue wounds describes BPC-157 promoting healing across several wound types (including incisional, burn, and diabetic-wound models), with no toxicity reached in the cited animal work. [Seiwerth 2021]
Central nervous system
BPC-157 has also been studied in rat models of central nervous system injury, where reviews describe effects in stroke and spinal-cord injury models, with proposed mechanisms involving the nitric-oxide system and dopamine signaling. All of this evidence is preclinical. [Vukojevic 2022]
The state of the evidence
The honest summary is that BPC-157 has robust preclinical support and minimal human data. A 2025 narrative review ("Regeneration or Risk?") found strong animal-model evidence but identified only a small number of human pilot studies, and concluded that well-designed clinical trials are needed before any clinical use. A favorable safety profile in animal studies does not establish safety or efficacy in humans. [McGuire 2025; Józwiak 2025]
For research use only
LUMEN BASED supplies BPC-157 strictly for laboratory and research use. It is not a drug, supplement, or therapeutic product, is not intended for human or veterinary use, and nothing on this page is medical advice or a claim of clinical benefit. Every reference below links to its primary source on PubMed for independent verification.
Verify the batch you're studying
Each BPC-157 lot ships with a third-party Certificate of Analysis (HPLC, mass spectrometry, identity confirmation). Pair the batch in your study with the matching COA before publishing or reporting results.
View COA for BPC-157 →References
- Józwiak M et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. PubMed
- Gwyer D et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. PubMed
- Seiwerth S et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. PubMed
- Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. PubMed
- Vukojevic J et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. PubMed
- McGuire FP et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PubMed
For Research Use Only. All LUMEN BASED compounds are strictly for in vitro laboratory research by qualified researchers. Not for human or animal consumption. Not approved by the FDA for therapeutic use.